Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company that researches, develops, and commercializes organ-selective medicines to treat immune system disorders and inflammation. The company reports its operations under a single segment: Discovery (research), Development and Commercialization of Human Therapeutics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Theravance Biopharma is advancing its pipeline candidates: TD-9855 in Phase III clinical studies for symptomatic neurogenic orthostatic hypotension (nOH). In FY2023, the company spent US$40.6 million on its R&D activities. Theravance Biopharma has an economic interest with regard to the Closed Triple drug development program for which future payments may be made by GSK or one of its affiliates following its agreements with Innoviva. Trelegy Ellipta has been approved for the treatment of COPD; GSK submitted filing to FDA for the use in patients with asthma. As of December 31, 2023, Theravance Biopharma owned 176 issued US patents and 1,002 granted foreign patents and several US patent applications and foreign patent applications. These patents cover lead compounds, product candidates, pharmaceutical compositions, methods of use and processes for making its compounds, and critical intermediates. Theravance Biopharma is also co-developing pipeline candidates for the treatment of gastroparesis; and post-operative gastrointestinal dysfunction (POGD IV) in collaboration with partners. As of December 31, 2023, Theravance Biopharma owned 176 issued US patents and 1,002 granted foreign patents and several US patent applications and foreign patent applications. These patents cover lead compounds, product candidates, pharmaceutical compositions, methods of use and processes for making its compounds, and critical intermediates.